Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Q Biotics Appoints Stephen Doyle As Chief Executive Officer

PRIVATEAug 05, 2024•almost 2 years ago

Position

Chief Executive Officer

Company

QBiotics Group Limited

Stephen Doyle

BrisbaneBiotechnologyHealth Care

Description

Stephen Doyle has been appointed as the Chief Executive Officer of QBiotics, effective from 2 September 2024. Stephen brings over 24 years of global pharmaceutical executive experience, with expertise in the discovery and development of new drugs, bringing them to market, and diversifying treatment options for patients.

Company Information

Company

QBiotics Group Limited

Location

Brisbane, Queensland, Australia

About

QBiotics is solving major health issues for humans and companion animals. We discover, develop and commercialise novel pharmaceuticals based on plant-derived cell-signalling molecules sourced from the Australian tropical rainforest, and underpinned by our discovery platform EcoLogic™. We simultaneously develop our products for the human and veterinary markets, delivering early to market veterinary products as well as real world animal data that informs and de-risks early stages of our human programmes. We currently have two leading programmes. The first is an oncology drug, tigilanol tiglate, with activity against a range of solid tumours. Tigilanol tiglate is now registered as a veterinary pharmaceutical, brand name STELFONTA®, and is marketed in the US, EU, UK and Australia. The drug is also currently in human Phase II clinical development. Our second programme is a pharmaceutical, EBC-1013, that addresses all the requirements for healing chronic and acute wounds. We have a very skilled and enthusiastic team of 61 employees.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for QBiotics Group Limited's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months